A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

NCT07557446 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteogenesis Imperfecta (OI)

Interventions

DRUG: AGA2115

Sponsor

Angitia Biopharmaceuticals Guangzhou Limited